Carl V Hamby

Summary

Affiliation: New York Medical College
Country: USA

Publications

  1. ncbi Expression of a catalytically inactive H118Y mutant of nm23-H2 suppresses the metastatic potential of line IV Cl 1 human melanoma cells
    C V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Int J Cancer 88:547-53. 2000
  2. ncbi Use of Peptide library screening to detect a previously unknown linear diagnostic epitope: proof of principle by use of lyme disease sera
    Carl V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Clin Diagn Lab Immunol 12:801-7. 2005

Research Grants

  1. SLT-VEGF for anti-angiogenic therapy of melanoma
    Carl Hamby; Fiscal Year: 2006

Collaborators

Detail Information

Publications2

  1. ncbi Expression of a catalytically inactive H118Y mutant of nm23-H2 suppresses the metastatic potential of line IV Cl 1 human melanoma cells
    C V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Int J Cancer 88:547-53. 2000
    ..These results imply that bound NDPK B promotes metastasis and suggest that inhibition of its function or of its binding to critical sites may be a useful approach to limit the development of metastases in human melanoma...
  2. ncbi Use of Peptide library screening to detect a previously unknown linear diagnostic epitope: proof of principle by use of lyme disease sera
    Carl V Hamby
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Clin Diagn Lab Immunol 12:801-7. 2005
    ....

Research Grants1

  1. SLT-VEGF for anti-angiogenic therapy of melanoma
    Carl Hamby; Fiscal Year: 2006
    ..The information obtained in this study will provide a rational basis for deciding whether SLT-VEGF alone or combined with IFN-alpha will be suitable for further development and testing in clinical trials with human patients. ..